International consensus guidelines for scoring the histopathological growth patterns of liver metastasis by Van Dam, Pieter Jan et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
International consensus guidelines for scoring the histopathological growth patterns
of liver metastasis
Van Dam, Pieter Jan; Van Der Stok, Eric P.; Teuwen, Laure Anne; Van Den Eynden, Gert G.;
Illemann, Martin; Frentzas, Sophia; Majeed, Ali W.; Eefsen, Rikke L.; Coebergh Van Den
Braak, Robert R.J.; Lazaris, Anthoula; Fernandez, Maria Celia; Galjart, Boris; Laerum, Ole
Didrik; Rayes, Roni; Grünhagen, Dirk J.; Van De Paer, Michelle; Sucaet, Yves; Mudhar,
Hardeep Singh; Schvimer, Michael; Nyström, Hanna; Kockx, Mark; Bird, Nigel C.; Vidal-
Vanaclocha, Fernando; Metrakos, Peter; Simoneau, Eve; Verhoef, Cornelis; Dirix, Luc Y.;
Van Laere, Steven; Gao, Zu Hua; Brodt, Pnina; Reynolds, Andrew R.; Vermeulen, Peter B.
Published in:
British Journal of Cancer
DOI:
10.1038/bjc.2017.334
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-SA
Citation for published version (APA):
Van Dam, P. J., Van Der Stok, E. P., Teuwen, L. A., Van Den Eynden, G. G., Illemann, M., Frentzas, S., ...
Vermeulen, P. B. (2017). International consensus guidelines for scoring the histopathological growth patterns of
liver metastasis. British Journal of Cancer, 117(10), 1427-1441. https://doi.org/10.1038/bjc.2017.334
Download date: 03. Feb. 2020
International consensus guidelines for scoring
the histopathological growth patterns of liver
metastasis
Pieter-Jan van Dam1, Eric P van der Stok2, Laure-Anne Teuwen1, Gert G Van den Eynden1, Martin Illemann3,
Sophia Frentzas4, Ali W Majeed5, Rikke L Eefsen6, Robert RJ Coebergh van den Braak2, Anthoula Lazaris7,
Maria Celia Fernandez8, Boris Galjart2, Ole Didrik Laerum9, Roni Rayes8, Dirk J Gru¨nhagen2, Michelle Van de paer1,10,
Yves Sucaet11,12, Hardeep Singh Mudhar13, Michael Schvimer14, Hanna Nystro¨m15, Mark Kockx10, Nigel C Bird16,
Fernando Vidal-Vanaclocha17, Peter Metrakos7, Eve Simoneau7, Cornelis Verhoef2, Luc Y Dirix1, Steven Van Laere1,
Zu-hua Gao18, Pnina Brodt8, Andrew R Reynolds*,4,19 and Peter B Vermeulen*,1,4,10
1Translational Cancer Research Unit, GZA Hospitals (St Augustinus), Wilrijk-Antwerp, Belgium; 2Department of Surgical Oncology, Erasmus MC
Cancer Institute, Rotterdam, The Netherlands; 3The Finsen Laboratory, Rigshospitalet/BRIC, Faculty of Health Sciences, University of Copenhagen,
Copenhagen, Denmark; 4Tumour Biology Team, Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK;
5Hepatobiliary Surgery, Sheffield Teaching Hospitals, Sheffield, UK; 6Department of Oncology, Naestved Hospital, Naestved, Denmark;
7Department of Surgery, Cancer Research Program, McGill University Health Centre Research Institute, Montreal, QC, Canada; 8Departments of
Surgery, Oncology and Medicine, McGill University and the McGill University Health Center Research Institute, Cancer Research Program,
Montreal, QC, Canada; 9The Finsen Laboratory and Department of Radiation Biology, Copenhagen University Hospital, University of Copenhagen,
Denmark; 10HistoGeneX, Sint-Bavostraat 78-80, Antwerp 2610, Belgium; 11Department of Pathology, Faculty of Medicine, Vrije Universiteit Brussel,
Brussels, Belgium; 12Pathomation, Berchem, Belgium; 13Department of Histopathology, Royal Hallamshire Hospital, Sheffield, UK; 14Institute of
Pathology, Sheba Medical Center, Tel Hashomer, Israel; 15Department of Surgery, Department of Surgical and Perioperative Sciences, Umeå
University, Umeå, Sweden; 16Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK; 17Valencia Institute of Pathology,
Catholic University of Valencia, Valencia, Spain; 18Department of Pathology and Oncology, McGill University, Montreal, QC, Canada and 19Early
Clinical Development, Innovative Medicines and Early Development, AstraZeneca, Cambridge, UK
Background: Liver metastases present with distinct histopathological growth patterns (HGPs), including the desmoplastic, pushing and
replacement HGPs and two rarer HGPs. The HGPs are defined owing to the distinct interface between the cancer cells and the adjacent normal
liver parenchyma that is present in each pattern and can be scored from standard haematoxylin-and-eosin-stained (H&E) tissue sections. The
current study provides consensus guidelines for scoring these HGPs.
Methods: Guidelines for defining the HGPs were established by a large international team. To assess the validity of these guidelines,
12 independent observers scored a set of 159 liver metastases and interobserver variability was measured. In an independent cohort of 374
patients with colorectal liver metastases (CRCLM), the impact of HGPs on overall survival after hepatectomy was determined.
Results: Good-to-excellent correlations (intraclass correlation coefficient 40.5) with the gold standard were obtained for the assessment of the
replacement HGP and desmoplastic HGP. Overall survival was significantly superior in the desmoplastic HGP subgroup compared with the
replacement or pushing HGP subgroup (P¼ 0.006).
Conclusions: The current guidelines allow for reproducible determination of liver metastasis HGPs. As HGPs impact overall survival after surgery
for CRCLM, they may serve as a novel biomarker for individualised therapies.
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Despite many years of basic and clinical research aimed at curbing
tumour growth, metastasis still remains the principle cause of
death in the majority of solid tumours. The liver is a frequent site
of metastasis for tumours originating from the gastrointestinal
tract, pancreas, breast and lung; the liver also hosts metastases of
renal cell carcinoma, melanoma and sarcoma (Disibio and French,
2008; Van den Eynden et al, 2013). For example, B80% of all
metastases from colorectal cancer (CRC) occur in the liver
(Schmoll et al, 2012). Approximately 20–25% of patients with
CRC present with liver metastases at the time of diagnosis with a
further 20–25% of patients expected to develop liver metastases at a
later date.
We and others have shown that the majority of metastases to
the liver present in one of three common distinct histopathological
growth patterns (HGPs), known as desmoplastic HGP, pushing
HGP or replacement HGP, and two rare HGPs. These HGPs are
distinguishable because the interface between the cancer cells of the
metastasis and the surrounding normal liver is distinct in each
growth pattern. Moreover, the HGPs are recognisable by light
microscopy in standard haematoxylin-and-eosin (H&E)-stained
tissue sections (Vermeulen et al, 2001; Stessels et al, 2004; Van den
Eynden et al, 2013). The distinct topography of cancer cells in each
HGP predicts HGP-specific interactions with parenchymal (hepa-
tocytes and cholangiocytes) and non-parenchymal cells (sinusoidal
endothelial cells, stellate cells and immune cells) of the liver.
However, despite these clear differences in the biology of these
metastases, the molecular drivers of the distinct HGPs remain
unknown. It is also currently unclear whether these distinct HGPs
require different clinical management strategies.
An overview of previous reports where these HGPs have been
studied is provided in Table 1. One of the most important
observations made in these studies is that liver metastases with a
replacement HGP do not rely on sprouting angiogenesis for a
vascular supply but instead co-opt the sinusoidal vasculature of the
liver (Vermeulen et al, 2001; Stessels et al, 2004; Frentzas et al,
2016). This is inferred from the specific morphology of replace-
ment-type liver metastases (Masson, 1923; Hamperl, 1956; Elias
and Bouldin, 1962; Elias et al, 1964; Vermeulen et al, 2001; Stessels
et al, 2004; Frentzas et al, 2016) and is consistent with the small
endothelial cell proliferation fraction reported in these metastases
(Stessels et al, 2004; Eefsen et al, 2012; Van den Eynden et al, 2012;
Vermeulen et al, 2002). This co-option of sinusoidal blood vessels
and peri-sinusoidal space (space of Disse) in the replacement HGP
is in contrast to the desmoplastic HGP where extensive stromal
remodelling and angiogenesis are observed (Vermeulen et al, 2001;
Frentzas et al, 2016). Desmoplastic liver metastases have an
upregulated uPA–uPAR–PAI-1 proteolytic system and an elevated
content of type I and type IV collagens (Illemann et al, 2009;
Nystrom et al, 2012; Eefsen et al, 2015).
Interestingly, there is some evidence that the HGP of CRC liver
metastases may be predicted by the histology of the primary
tumour. Primary CRCs can be classified as having a pushing
margin or an infiltrative margin as defined by Jass et al (1987).
When liver metastases were classified as being ‘encapsulated’
(which probably corresponds to the desmoplastic HGP) or non-
encapsulated (which probably corresponds to pushing HGP or
replacement HGP), 69% of the primary CRCs with pushing
margins, as defined by the Jass criteria (Jass et al, 1987), developed
encapsulated liver metastases while only 17% of primary CRCs
with an infiltrative margin developed encapsulated liver metastases
(Rajaganeshan et al, 2007). The type of primary cancer can also be
predictive of the liver metastases HGP, as almost all breast cancer
liver metastases adopt a replacement growth pattern, while liver
metastases of CRC can present with any of the different HGPs
described (Stessels et al, 2004; Frentzas et al, 2016).
Importantly, the HGPs of liver metastases were shown to have
prognostic significance. Both Van den Eynden et al (2012) and
Nielsen et al (2014) studied the impact of the HGPs on overall
survival in patients with metastatic CRC. In both studies, the
desmoplastic HGP represented superior overall survival. However,
in these studies, the results regarding the relative incidence of the
different HGPs and the prognostic values of the replacement and
pushing HGPs were contradictory. These contradicting results may
have been a consequence of differences in the treatment history of
the patients in both studies or due to the low number of patient
samples that were examined but were likely also due to differences
in the methodology used to assess the HGPs. These disparities
highlight the need to develop consensus guidelines for scoring the
HGPs of liver metastases.
A second important reason to develop such guidelines is the
emerging prognostic or predictive value of the HGPs. The clinical
and biological diversity of, for instance, CRC liver metastases
indeed urges the need for predictive biomarkers to facilitate tailor-
made treatment strategies (Poston, 2008; Poston et al, 2008).
Frentzas et al (2016) demonstrated that CRC liver metastases with
a replacement HGP respond poorly to bevacizumab treatment,
likely because these tumours utilise vessel co-option instead of
angiogenesis. By contrast, desmoplastic liver metastases, which are
angiogenic, showed a better response to bevacizumab (Frentzas
et al, 2016). These data strongly suggest that HGPs can be used to
guide the choice of treatment for individual patients with liver
metastases.
Finally, guidelines for scoring the HGPs of liver metastases are
important for future mechanistic studies that are aimed at
elucidating the molecular drivers of each HGP. These studies will
require the establishment of preclinical liver metastasis models that
mimic the distinct growth patterns using established cell lines or
patient-derived xenografts (PDXs). Studies using such models
should lead to identification of novel targets to facilitate precision
treatments for patients with liver metastases.
The aims of the current manuscript are therefore to (a) propose
consensus guidelines for scoring the HGPs of liver metastases, (b)
test the analytical validity of these guidelines, (c) validate the
prognostic significance of the HGPs of liver metastasis, (d)
speculate on the molecular mechanisms that may underlie the
differences in the growth patterns, and (e) highlight future research
directions for growth pattern research.
METHODS
Constructing the guidelines. The team of experts responsible for
the proposed guidelines consists of members of the Liver
Metastasis Research Network (www.lmrn.org) all of whom have
had experience in the assessment of the HGPs of liver metastases.
Based on many observations in previous studies on HGPs
(Vermeulen et al, 2001, 2002; Eefsen et al, 2012, 2015; Van den
Eynden et al, 2012, 2013; Frentzas et al, 2016), and consequently
multiple discussions at annual meetings of the LMRN, consensus
was reached on a systematic approach to assessing the HGPs. A
draft manuscript was produced by a writing committee and was
circulated to all the co-authors. Final approval of the guidelines
occurred during the annual meeting of the LMRN on 16–17 June
2016 in Umeå, Sweden.
Agreement in HGP score between different samples from the
same metastasis. The extent of agreement in HGP score between
different samples from the same lesion was addressed in 50 liver
metastases of CRC for which X4 formalin-fixed-paraffin-
embedded (FFPE) blocks were available for scoring. The samples
used for this analysis were obtained from the Department of
Surgical Oncology of the Erasmus MC Cancer Institute (Rotter-
dam, The Netherlands). The total number of blocks included in the
analysis was 234, median number of blocks available per lesion was
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Table 1. Overview of the studies that have addressed the association of the histopathological growth patterns (HGP) of liver
metastases with clinical and pathological parameters
First author
Reference (in chronological
order) Methodology Study population Main results
Masson P Les Tumeurs. In: Traite´ de Pathol
et The´rapie applique´es par
Sergent, Ribadeau-Dumas et
Babonneix, 1923, Vol. 27, Part II
Histology: H&E or comparable
stain
Case reports Description of replacement,
sinusoidal and desmoplastic
growth patterns
Hamperl H U¨ber die Gutartigkeit und
Bo¨sartigkeit von Geschwu¨lsten.
Verh Dtsch Ges Path 35, 1951, 29
Histology: silver stain Case reports Description of replacement
growth and sinusoidal growth
Elias H Acta Hepato-Splenol 1962; 9:
357–386
Oncology (International Journal of
Cancer Research and Treatment)
1964; 18(3): 210–224
Histology: H&E, silver stain 23 autopsy cases 4 growth patterns: expansive,
invasive, destructive, replacing
Description of the replacement
of normal hepatocytes by tumour
cells: ‘normal liver cells join a
tumour at its periphery’
‘Carcinoma cells are located
within liver plates together with
structurally normal liver cells
without signs of compression or
lysis of the latter’
Nakashima T Hum Pathol 1982; 13: 563–568 Histology: H&E, silver stain
Growth pattern assessment at the
boundary between tumour and
liver parenchyma
HCC, 24 autopsy liver specimens
(no chemotherapy)
3 growth patterns: sinusoidal
(25%), replacing (46%),
encapsulated (29%)
Association of HGP with degree
of differentiation (anaplastic,
intermediate, well differentiated
(respectively))
Incorporation of some
hepatocytes in the tumour in the
sinusoidal and replacing growth
pattern
Terayama N Jpn J Clin Oncol 1996; 26: 24–29 Histology: H&E, silver stain
Growth pattern assessment at the
boundary between tumour and
liver parenchyma
Liver metastasis, 100 autopsy liver
specimens (lung, pancreas,
stomach, gallbladder/bile duct,
colon cancer)
5 parenchymal growth patterns:
sinusoidal, replacement,
encapsulated, expansive,
unclassified
Growth pattern frequency
dependent on cancer histiotype
(portal growth (resembling
lymphangitis carcinomatosa of
the lung) in poorly differentiated
cases)
Higher frequency of replacement
growth in small metastases
Terayama N Hepatology 1996; 24: 816–819 IHC for vWF, histochemistry with
UEA-I
3D-morphometry after vascular
casting
Same study population as above Phenotypic changes of sinusoidal
blood vessels in the adjacent liver
parenchyma
In small metastases: sinusoidal
blood vessels in continuity with
blood vessels of liver metastases
Blood vessel density increased
according to the size up to 3mm
in diameter, remaining stable
over 3mm
Okano K Cancer 2000; 89: 267–75 Histology: H&E
Presence of fibrous tissue between
tumour and liver parenchyma:
none, thin, thick (X10 layers of
collagen bundles)
Liver metastases of 152 patients
with CRC; liver resection with
curative intent (30%/70%
synchronous/metachronous)
No (pseudo)capsule (39%), thin
(30%), thick (31%)
No association of HGP with size
or histological differentiation of
the metastases
Thick capsule associated with
intrabile ductal growth, no
capsule associated with vascular
invasion
Thick capsule associated with
better overall survival
(multivariate analysis)
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Table 1. ( Continued )
First author
Reference (in chronological
order) Methodology Study population Main results
Lunevicius R J Cancer Res Clin Oncol 2001;
127:193–199 (comparable results
in: Ohlsson B et al, World J Surg
1998; 22:268-277 and Morino T
et al, Arch Jpn Chir 1991;
60: 154–164)
Histology: H&E
Non-capsule: tumour cells face the
hepatic parenchyma directly (no
fibrous capsule); Capsule: fibrous
band of 0,5mm thickness or more
Intermediate
IHC for a-smooth muscle actin,
desmin, vimentin, CD-8, CD-68,
collagen Type I, MMP-1, MMP-2
and TIMP-1
Liver metastases of 69 patients
with CRC
Non-capsule (45%), intermediate
(35%), capsule (20%)¼20%
‘encapsulated’
Encapsulation more frequently
around differentiated metastatic
cancers
Increased survival rates related to
encapsulation (5 year, not
long-term)
Vermeulen PB J Pathol 2001; 195: 336–342 Histology: H&E, silver stain
Liver metastasis HGP
(dominant HGP)
IHC: double-staining for CD31/
Ki67 and for CD34/ a-SMA
IHC for caspase cleavage site
of CK18
Liver metastases of 26 patients
with CRC (chemonaive/elective
surgery/one metastasis per
patient)
Desmoplastic (42%), pushing
(46%), replacement (12%) (dense,
mild and no inflammatory
infiltrate, respectively)
Highest ECP and highest
ECP/TCP in pushing HGP
Higher fraction of immature
microvessels in the desmoplastic
versus the pushing GP
Stessels F British Journal of Cancer 2004; 90,
1429–1436
Histology: H&E
Liver metastasis HGP (according to
Vermeulen et al, 2001)
IHC for CAIX, CD68, fibrin, LYVE-1
Liver metastases of 45 patients
with BC (28 necropsy cases) and
28 patients with CRC (surgical
resection specimens)
HGP is cancer type-dependent.
BC: desmoplastic (2%), pushing
(2%), replacement (96%); CRC:
desmoplastic (50%), pushing
(18%), replacement (32%)
Less CAIX, less fibrin and less
macrophages in the BC
metastases and in the
replacement-type metastases
of CRC
Cooption of LYVE-1-positive
sinusoidal blood vessels in
replacement HGP
Allison KH Arch Pathol Lab Med 2004; 128:
1418–1423
Histology: H&E Case reports of occult breast
cancer invasion of the liver (and
review of literature)
Liver failure and death due to
breast cancer metastasis in the
liver with sinusoidal growth
pattern
Rajaganeshan R British Journal of Cancer 2007;
96: 1112–1117
Histology: H&E
Invasive margin of primary CRC
(according to Jass et al, 1987)
Liver metastasis HGP (according to
Lunevicius et al, 2001)
IHC for CD31: computer-aided
image analysis to determine MVD
Liver metastases of 55 patients
with colorectal cancer; resection
with curative intent (53%/47%
synchronous/metachronous)
Association between HGP of
primary CRC and HGP of liver
metastases (pushing and
capsulated; infiltrative and
noncapsulated, respectively)
Positive correlation of MVD at the
tumour margin of primary CRC
and matched liver metastases
Illeman M Int J Cancer 2009; 124: 1860–1870
Comment by Van den Eynden G
et al Int J Cancer 2009;
125: 1494–1495
Histology: silver stain
Liver metastasis HGP (according to
Vermeulen et al, 2001)
Invasive margin of primary CRC
(according to Jass-criteria)
IHC: uPAR, PAI-1, LN5g2
ISH: uPA
14 liver metastases and matched
primary CRC (14 patients (1–5
metastases/patient)) (43%/57%
synchronous/metachronous)
No correlation between the
degree of cancer cell budding in
the CRC and the HGP of liver
metastases
Desmoplastic GP (43%), pushing
(57%), replacement (0%)
Upregulation (as in all primary
CRC) of uPA–PAI system in 5/6
desmoplastic o4 0/8 pushing
metastases
Differences between activity of
uPA–PAI system between
primary breast carcinoma and
liver metastases of breast cancer
Nystro¨m H Anticancer Research 2012; 32:
5183–5192
Histology: H&E and chemical
reticular staining; dominant
pattern was used, largest
metastasis was used if multiple
metastases
Picro-Sirius Red staining for type I
and type III collagens
IHC for type I and type IV
collagens
HGP according to Vermeulen
et al, 2001
Liver metastases of 48 patients
with colorectal cancer (fraction
with neo-adjuvant treatment)
Desmoplastic (47%) and pushing
(53%), no replacement HGP (0%)
Higher levels of type I and type IV
collagen in desmoplastic
metastases
Shorter overall survival in patients
with pushing metastases
No prediction of HGP by
analysing the characteristics of
the primary CRC
No association of size of the liver
metastases and HGP
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Table 1. ( Continued )
First author
Reference (in chronological
order) Methodology Study population Main results
Van den
Eynden G
Clin Exp Metastasis 2012;
29: 541–549
Histology: H&E, silver stain
HGP assessment at the boundary
between tumour and liver
parenchyma: one GP if 475% of
interface, mixed if GPs 425% of
interface
IHC double-staining for CD34/
Ki67 and staining for CAIX
Liver metastases of 205 patients
with colorectal cancer; resections
with curative intent (50%/50%
synchronous /metachronous)
27,8% replacement; 15,6%
pushing; 34,6% desmoplastic;
17,6% mixed (n¼ 9:insufficient
sampling of interface)
ECP (%) highest in pushing HGP,
TCP (%) lowest in replacement
HGP
Higher ECP and TCP if CAIX
expression at interface
Metastases with pushing HGP
larger than desmoplastic/
replacement HGP
At 2 year FU: lower survival
fraction in the group with
pushing component
Løvendahl
Eefsen R
Journal of Oncology 2012; Article
ID 907971, 12 pages
Histology: H&E, silver stain
HGP assessment at the boundary
between tumour and liver
parenchyma: one HGP if475% of
the visualised interface, mixed if
GPs 425% of the visualised
interface (according to Vermeulen
et al, 2001)
IHC for CD31, uPAR
IHC double-staining for CD34/
Ki67
62 liver metastases obtained from
24 chemonaive patients with CRC
(21 (88%) patients with
synchronous metastases)
4 observers for HGP scoring:
inter-observer kappa-values:
0.52–0.69 (due to ‘mixed’ versus
‘uniform’ pattern scoring
differences)
Desmoplastic (25.8%), pushing
(33.9%), replacement (21%),
mixed (19.3%)
20 out of 24 patients with same
HGP in all metastases
Elevated expression of uPAR in
desmoplastic and replacement
HGP
ECP/TCP highest in the pushing
HGP
No association of primary tumour
characteristics (obtained from
pathology report) and HGP
Simone C Journal of Medical Case Reports
2012; 6: 402
Histology: H&E Case reports of occult cancer
invasion of the liver (and review of
literature)
Liver failure and death due to
cancer metastasis in the liver with
sinusoidal growth pattern
Nielsen K Mod Pathol 2014; 27: 1641–1648 Histology: H&E, silver stain (?)
(according to Vermeulen et al,
2001; 75% cutoff for dominant
growth pattern)
217 liver metastases obtained
from 217 patients with CRC
(treatment data not available)
22 re-resections of 16 patients
Pushing (33%), desmoplastic
(32%), replacement (11%), mixed
growth pattern (24%)
Desmoplastic metastases were
significantly smaller
Replacement growth pattern
related to shorter overall survival
In 13 out of 22 recurrent
metastases, a new growth
pattern was found
Pinheiro RS Am J Surg 2014; 207: 493–498 Histology: H&E (according to
criteria reported by Jass et al for
primary CRC: ’pushing’ and
‘infiltrative’
91 patients with CRC liver
metastases (mean number of
lesions of 2.9)
Infiltrative margins (resembling
replacement growth) as
independent risk factor for
recurrence and inferior 5-year
DFS rate
Eefsen RL Clin Exp Metastasis 2015; 32:
369–381
Histology: H&E, silver stain
(according to Vermeulen et al,
2001; 75% cutoff for dominant
growth pattern)
224 CRC liver metastases
obtained from 224 patients
(largest metastasis only)
Recurrence-free survival longer if
desmoplastic HGP then if
replacement HGP (both for
chemonaive patients and
patients who received neo-
adjuvant treatment)
Eefsen RL Cancer Microenviron 2015; 8(2):
93–100
Histology: H&E, silver stain
(according to Vermeulen et al,
2001; 75% cutoff for dominant
growth pattern)
IHC for uPAR, CD3, CD68
237 CRC liver metastases from 237
patients (selection of one
metastasis per patient based on
regression grade)
In untreated patients only: higher
expression of uPAR in the
desmoplastic HGP and higher
number of macrophages (CD68)
in the replacement HGP
Kuczynski EA J Natl Cancer Inst 2016; 108 (8) Histology
Contrast-enhanced ultrasound
(vessel perfusion)
miRNA sequencing and qRT-PCR
Orthotopic human HCC model to
study sorafenib resistance
Resistance based on a change of
growth pattern with vessel
co-option during treatment
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4 (range¼ 4–16 blocks per lesion). H&E-stained sections from all
234 blocks were scored for HGP by EPvdS, RRJCvdB, BG and PBV
according to the proposed guidelines (a consensus score was agreed
upon during multiple sessions at a multihead microscope). Each
block was then assigned to an HGP category: those scored as
450% desmoplastic were categorised as predominant desmoplas-
tic HGP (n¼ 121 blocks), those scored as 450% pushing were
categorised as predominant pushing HGP (n¼ 7 blocks), and those
scored as 450% replacement were categorised as predominant
replacement HGP (n¼ 98 blocks). In the case that no predominant
HGP was found, the block was categorised as having a mixed HGP
(n¼ 8 blocks). In order to determine the extent of agreement in
HGP score between different blocks derived from the same lesion,
for each of the 50 lesions we calculated the percentage of blocks
that fell into the same category.
Analytical validation study. For the analytical validation of the
guidelines, representative H&E-stained sections from 159 FFPE
sections of CRC (n¼ 129) and breast cancer (BC) (n¼ 30) liver
metastases (obtained from patients undergoing routine resection)
were retrieved from the archives of the pathology laboratory of the
St Augustinus Hospital (GZA Hospitals), Wilrijk-Antwerp,
Belgium. This set was then divided into a training set of 60
metastases and a validation set of 99 metastases by PBV and
GGvdE. The sections were scanned on a 3DHISTECH (3DHIS-
TECH Ltd., Budapest, Hungary) scanning device. Explanatory
notes were provided for each of the images in the training set.
These notes included the ‘gold standard’ HGP score, that is, the
consensus HGP score as agreed by two pathologists (PBV and
GGvdE) with 410 years of experience in scoring the HGPs. The
images and the explanatory notes were then uploaded to the
‘Pathomation whole slide image viewer’ (Pathomation BVBA,
Antwerp, Belgium) on the website of the Liver Metastasis Research
Network (www.lmrn.org). The decision tree and the guidelines
(Figure 1 and Tables 2 and 3, respectively) were also published on
this website.
Twelve participants volunteered to take part in the validation
study. Of these 12 participants, only 4 had prior experience of
scoring liver metastasis growth patterns, while the remaining 8
participants had no prior experience of scoring liver metastasis
growth patterns. Of these 12 participants, only 3 were
professionally trained pathologists, while the remaining 9
participants were scientists with either a biological sciences or
medical background. Participants were given access to the data
on the website of the Liver Metastasis Research Network. The
participants were first asked to study the decision tree and the
guidelines so that they could understand how HGPs are to be
scored. They were then asked to examine the training set and the
explanatory notes. Once these tasks were completed, they were
then given access to the validation set of 99 liver metastases and
asked to record their HGP scores for each of the cases. The
participants assessed the HGPs of each metastasis (percentage of
interface occupied by a growth pattern for all growth patterns
present in 45% of the length of the interface) and submitted
their results electronically within the Pathomation image viewer.
The submitted results were then compared with the preestab-
lished ‘gold standard’.
Clinical validation study. The clinical validity was assessed by a
survival analysis. For this we used representative H&E-stained
tissue sections of FFPE CRC liver metastases from 374 patients
who underwent surgical resection at the Department of Surgical
Oncology of the Erasmus MC Cancer Institute (Rotterdam, The
Netherlands) between 2000 and 2015. The HGPs were determined
by EPvdS, RRJCvdB, BG and PBV according to the proposed
guidelines (for patient details, see Table 4). A consensus score was
agreed upon during multiple sessions at a multihead microscope.
Patients for whom 450% of the tumour–liver interface was
identified as exhibiting one of the three HGP were allocated to a
group labelled as predominantly of this HGP (i.e., 450%
desmoplastic were categorised as predominant desmoplastic
HGP; 450% pushing were categorised as predominant pushing
HGP; 450% replacement were categorised as predominant
replacement HGP). In cases of multiple sections per metastasis
or multiple liver metastases per patient, the mean percentage was
used. Overall survival was considered the time interval between the
date of liver metastasis resection and the date of death or last
follow-up.
Overall survival analysis using different HGP cutoffs. Survival
analyses were also performed using different cut points to define
the predominant HGP. Owing to the low numbers of patients
presenting with a predominant pushing HGP (only 3% of patients
when using a cutoff of 450%), this analysis was limited to a
comparison of replacement HGP patients with desmoplastic HGP
patients. Cut points of 450%, 470%, 480%, 490% or 100%
were used to define whether a tumour had a predominant
replacement HGP or a predominant desmoplastic HGP.
Statistical analysis. Descriptive values are expressed as median
(interquartile range). Variables were compared by chi-square
analysis, Fisher’s exact test or with independent Student’s t-test or
Mann–Whitney U-test. The Kaplan–Meier method was used to
generate survival estimates, which were compared by Log-rank test.
Cox regression models were used to correct for potential
confounders. Only parameters with a P-valueo0.10 in the
univariate model were entered in the multivariate Cox regression
Table 1. ( Continued )
First author
Reference (in chronological
order) Methodology Study population Main results
Siriwardana PN Medicine 2016; 95(8): e2924 Histology: H&E (‘infiltrative’ and
‘encapsulated’ HGP; 75% cutoff
for dominant growth pattern)
30 patients with CRC liver
metastases. No presurgical
systemic treatment. One randomly
selected metastasis per patient
Longer overall survival if
encapsulated liver metastasis
Frentzas S Nature Medicine 2016; 22:
1294–1302
Histology: H&E (according to the
current guidelines)
152 CRC liver metastases from 79
patients
The HGPs predict response to
bevacizumab chemotherapy
treatment and survival. Patients
with liver metastases with a
replacement growth pattern have
a less favourable outcome
Abbreviations: BC¼breast cancer; CRC¼ colorectal cancer; DFS¼disease-free survival; ECP¼ endothelial cell proliferation; FU¼ follow-up; HCC¼ hepatocellular carcinoma;
H&E¼ haematoxylin and eosin; HGP¼ histopathological growth pattern; IHC¼ immunohistochemical; ISH¼ in situ hybridisation; miRNA¼microRNA; MMP¼matrix metalloprotease;
MVD¼microvessel density; PAI-1¼ type 1 plasminogen activator inhibitor; qRT-PCR¼quantitative reverse transcriptase-PCR; SMA¼ smooth muscle actin; TCP¼ tumour cell proliferation;
TIMP¼ tissue inhibitor of metalloproteinase; UEA-1¼Ulex europaeus agglutinin I; uPA¼ urokinase plasminogen activator; uPAR¼ uPA receptor; vWF¼ von Willebrand factor; 3D¼ three
dimensional.
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Table 2. Key histopathological characteristics of the growth patterns of liver metastases
Histology of interface Desmoplastic Pushing
Replacement (two
types) Sinusoidal Portal
Obligatory criteria
Architecture Desmoplastic rim
between liver and
metastatic tissue
Liver pushed aside by
metastatic tissue
Hepatocytes are
replaced by cancer
cells
Cancer cells grow in the
sinusoidal vessels or in
the peri-sinusoidal space
(Disse)
Proliferation of
cancer cells within
portal tracts and
septa
Mimicking of liver architecture   þ þ þ 
Invasion around sinusoidal
capillaries
  þ (þDisse space) þ þ 
Invasion of cancer cells in the
liver cell plates with direct
contact between hepatocytes
and cancer cells
  þ þ  
Desmoplastic reaction þ þ     /þ
Compression of liver cell plates þ þ þ  /þ  
Contour Sharp Sharp Irregular Irregular Sharp
Additional criteria
Inflammatory infiltrate þ þ þ / a  a  a þ
Glandular differentiation
(adenocarcinoma)
Well differentiated Well differentiated Moderately to poorly
differentiated
Poorly differentiated Well to moderately
differentiated
Proliferation of bile ducts þ /     /þ
Caution
Portal tracts Do not score as desmoplastic area
Liver capsule Do not score HGP when near liver capsule
Abbreviation: HGP¼histopathological growth pattern.
aTreatment-related inflammation can be present.
Are cancer cells
present in the
sinusoidal blood
vessels or peri-
sinusoidal space in
between the liver cell
plates ?
Yes
Sinusoidal HGP
(uncommon)
No
Is the metastasis
separated from the
liver tissue  by a
desmoplastic rim?
Yes
Desmoplastic HGP
No
Do the cancer
cells form plates
in continuity
with the liver cell
plates and
perpendicular to
the tumour–liver
interface?
Yes
Replacement HGP
(type 1)
No
Liver cell plates are
compressed and
pushed away with or
without cancer cells
invading the liver cell
plates.
Without invasion
Pushing HGP
With invasion
Replacement HGP
(type 2)
Is the metastasis
restricted to the
portal tracts?
Yes
Portal HGP
(uncommon, *)
No
* Exceptional non-parenchymal growth of
liver metastases: endobiliary growth,
resembling cholangiocarcinoma
Figure 1. Decision tree to assess the growth patterns of liver metastases based on the key histopathological characteristics.
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model. The SPSS statistical package (version 21.0, SPSS, Chicago,
IL, USA) was used. A P-valuep0.05 was considered statistically
significant.
RESULTS
Guidelines for scoring the HGPs of liver metastases. In these
guidelines, three common (desmoplastic HGP, pushing HGP and
replacement HGP) and two rare (sinusoidal HGP and portal HGP)
growth patterns are described that can all be identified in H&E-
stained specimens of FFPE liver metastases. The key histopatho-
logical characteristics of the HGPs are summarised in Table 2. The
consensus guidelines for scoring the HGPs are summarised in
Table 3. In order to assist the observer in scoring the different
HGPs, we have constructed a decision tree that can be easily
followed to determine the growth pattern (Figure 1).
In the desmoplastic HGP, the cancer cells of the metastasis are
separated from the liver tissue by a rim of desmoplastic tissue
(Figures 2A–D). The metastasis does not mimic the liver
architecture and there is no direct contact between cancer cells
and hepatocytes. New blood vessels in the desmoplastic rim are
formed by sprouting angiogenesis. There is often a dense
lymphocytic infiltrate at the interface of the desmoplastic and
liver tissue that can sometimes obscure the interface (Figure 2E).
A proliferation of bile ducts, often called ‘ductular reaction’, can
sometimes be seen surrounding the desmoplastic metastasis
(Figure 2E). It is important to note that portal tracts that lie
directly adjacent to a metastasis should not be confused with the
desmoplastic tissue (Figure 2F). Also, areas directly underneath the
liver capsule should not be confused with desmoplastic tissue.
In the pushing HGP, the liver cell plates that surround the
metastasis are pushed away and are compressed (Figures 3A–C).
There is no desmoplastic rim surrounding the metastasis but also
no direct contact between cancer cells and hepatocytes within the
liver cell plates. As in the desmoplastic HGP, the metastasis does
not mimic the liver architecture.
In the replacement HGP, cancer cells form cell plates that are in
continuity with the liver cell plates (Figures 4A–E). This permits
the cancer cells to replace the hepatocytes within the liver cell
plates and allows these metastases to co-opt the sinusoidal blood
vessels at the tumour–liver interface, without inducing sprouting
angiogenesis. There are two subtypes of the replacement HGP. In
the first type (type 1) the liver cell plates used by the cancer cells
are perpendicular to the tumour–liver interface (Figures 4B and C),
and in the second type (type 2), the liver cell plates are pushed
away while the cancer cells replace the hepatocytes (Figures 4D and
E). The latter type of replacement HGP should not be confused
with the pushing HGP (Figures 3A–C).
There are two rare HGPs of liver metastases, namely, the
sinusoidal HGP and the portal HGP. In the sinusoidal HGP, the
cancer cells are present as emboli within the lumens of the
sinusoidal blood vessels and/or grow in the peri-sinusoidal space
(Figure 5). As the cancer cells do not exit the blood vessels or enter
the liver cell plates, there is no cell–cell contact between the cancer
cells and the hepatocytes in this sinusoidal HGP. As in the
replacement HGP, the sinusoidal blood vessels are co-opted as a
means of vascularisation. In our experience, the sinusoidal HGP
occurs in patients with rapidly progressing liver metastases and is
therefore often encountered in autopsy specimens (Allison et al,
2004; Simone et al, 2012). In the portal HGP, the growth of cancer
is restricted to the connective tissue areas of the portal tracts, liver
septa and liver capsule. The portal HGP has been detected in
animal models of liver metastases by us and only very infrequently
in human BC or CRC liver metastases.
The current guidelines also address the fact that a liver
metastasis may have more than one growth pattern. In order to
collect all the available information for subsequent data analysis,
the guidelines propose to estimate the relative fraction of each
Table 4. Clinicopathological characteristics in the clinical
validation cohort
All patients (N¼374)
Variables Value % or IQR
Male 241 64%
Age, median 63 57–70
Primary tumour
Rectal cancer 170 46%
T3/T4 273 79%
Positive lymph node 211 61%
Adjuvant CTx 70 19%
Liver metastases
CEA 4200 ngml1 23 8%
Synchronous (o1 year) 243 66%
Diameter Largest 45 cm 67 18%
Number of metastases 41 234 63%
Bilobar 153 41%
Neo-adjuvant Ctx 206 56%
Neo-adjuvant Ctxþbevacizumab 59 16%
R1 resection 99 27%
Extrahepatic disease 45 12%
CRS 3–5 139 38%
Abbreviations: CEA¼ carcinoembryonic antigen; CRS¼ clinical risk score; CTx¼
chemotherapy; IQR¼ interquartile range.
Table 3. Standard method for histopathological growth
pattern assessment of liver metastases
 The growth pattern is a histological parameter assessed by light
microscopic imaging of haematoxylin-and-eosin sections of FFPE tissue of
liver metastases.
 The histological growth patterns of liver metastases can be evaluated by a
pathologist or by any other investigator trained by a pathologist.
 The growth pattern is a characteristic of the tumour–liver interface. The
centre of the metastasis does not contribute to the classification of a
growth pattern.
 A histochemical silver impregnation staining of the sections (e.g., Gordon–
Sweet’s reticulin staining) has added value to discern fibrosis/preservation
of the supportive tissue architecture of the spaces of Disse and sinusoids.
 The three common growth patterns are: desmoplastic, pushing and
replacement (type 1 and type 2).
 Two rare growth patterns are: sinusoidal and portal.
 When more than one growth pattern is present in a metastasis: estimate
the relative fraction of each growth pattern with a length of X5% of the
total length of the interface (e.g., 80% desmoplastic/20% pushing; 95%
replacement/5% pushing).
 In case of multiple metastases/patient: assess the growth pattern(s) in every
individual liver metastasis and note the anatomical position.
 Caveats.
J Portal tracts at the tumour–liver interface should not be evaluated as
areas with a desmoplastic growth pattern.
J Reactive ductular proliferation in the desmoplastic rim can simulate a
replacement growth pattern.
J Metastases with a replacement growth pattern usually have no or a very
mild inflammatory infiltrate. Exceptionally, these metastases can have a
dense infiltrate.
J Metastases adjacent to the liver capsule should be assessed with
caution to avoid overestimation of desmoplastic growth.
J Tissue cores from needle biopsy procedures cannot be used to assess
the growth pattern of liver metastases.
J If o20% of the expected interface is present in the tissue section, a
disclaimer stating ‘insufficient tumour–liver interface’ should be added.
J Delayed fixation (e.g., autopsy cases) or radiofrequency ablation can
impair the quality of the tissue so that reliable assessment of growth
patterns is not possible.
J If no viable tumour tissue is present in the metastasis, this should be
mentioned (treatment effect: fibrosis, infarct-type necrosis, acellular
mucin lakes).
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HGP that constitutes X5% of the total length of the interface.
In the typical pathology archive, there may be either one tissue
block available per liver lesion or multiple tissue blocks available
per liver lesion. In the case where multiple blocks are available for a
given lesion, we recommend that the HGP from each block is
determined. The mean average HGP score should then be
calculated to produce a single score for percentage of desmoplastic,
percentage of pushing and percentage of replacement HGP for
each lesion. In case of multiple liver metastases from a single
patient, it is recommended that the HGPs of every individual single
lesion be scored separately and the information saved together with
the anatomical position of the respective lesion.
Important caveats for scoring the HGPs of liver metastases. In
order to score the HGPs correctly, there are issues of concern that
are related to the amount of available tumour–liver interface
(where the HGPs are assessed), the quality of the tissue and the
process of data collection. These points of concern are summarised
in Table 3. First, tissue cores from needle biopsy procedures should
not be used to assess the HGPs of liver metastases. The obvious
reason is that the amount of interface present in a tissue core is
minimal and insufficient to cover the possible heterogeneity of the
HGPs within a single metastasis. Second, ifo20% of the expected
interface is present in the tissue section, a disclaimer stating
‘insufficient tumour–liver interface’ should be added. There are
various circumstances that may cause o20% of the expected
interface to be present in the tissue section. These include, but are
not limited to, the following: (a) the presence of excessive damage
to the tissue section or (b) when a considerable proportion of the
tumour present in the section forms a border with the liver capsule
rather than forming a border with the liver parenchyma. Third, if
no viable tumour tissue is present in the metastasis, scoring the
HGP is not possible. Often this is due to treatment before surgery
that causes replacement of the cancerous tissue by areas of fibrosis,
infarct-type necrosis or cell-free lakes of mucinous substance.
Fourth, an adequate quality of the liver metastasis tissue is
essential. Indeed, delayed fixation (e.g., autopsy cases) or radio-
frequency ablation can impair the quality of the tissue so that
reliable assessment of HGPs is not possible.
Agreement in HGP score between different samples from the
same metastasis. When considering the diagnostic utility of the
HGPs, one point of concern is whether a single tissue section
adequately captures the growth pattern of the entire lesion. In
order to address this issue, we examined whether scoring the HGP
from a single tissue sample is as accurate as scoring the HGP from
multiple tissue samples. To do this, we examined an unselected set
of 50 liver metastases for which multiple (X4) tissue blocks were
available. The median number of blocks available per lesion in this
set was four (range¼ 4–16 blocks per lesion). A single tissue
section from each block was scored for the HGP and then assigned
to an HGP category: predominant desmoplastic HGP, predomi-
nant pushing HGP, predominant replacement HGP, or mixed
HGP (according to strictly defined criteria, as detailed in the
Methods section). We then assessed the degree to which blocks
from the same lesion fell into the same category. We found that, for
82% of the lesions examined (41 out of 50 lesions), the HGP
category was in complete agreement (100% agreement) across all
blocks tested. Among the 9 other lesions examined,
we found agreement between: 4 out of 5 blocks (80% agreement)
for two lesions, 3 out of 4 blocks (75% agreement) for 4 lesions, 3
out of 5 blocks for 2 lesions (60% agreement), and 2 out of 4 blocks
for 1 lesion (50% agreement). There were no cases with an
agreement o50%.
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Figure 2. H&E images of the desmoplastic histopathological growth pattern. (A–C) Low magnification images of the desmoplastic
histopathological growth pattern. (D) Higher magnification image of the desmoplastic histopathological growth pattern. (E) Desmoplastic
histopathological growth pattern with ductular proliferation (also known as ductular reaction) and dense lymphocyte infiltrate. (F) Portal tracts at the
tumour–liver interface. D, desmoplastic rim; DP, ductular proliferation; L, lymphocyte infiltrate; N, normal liver parenchyma; PT, portal tract; T,
vital tumour tissue. Scale bar¼ 1000mM (A–C and F), 100mM (D and E).
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Analytical validation of the guidelines to assess the HGPs of
liver metastasis. In order to assess the analytical validity of the
current guidelines, a validation study was performed. In the first
stage, 12 participants (a mixed group composed of 3 pathologists, 4
clinicians and 5 basic scientists) underwent a training exercise, in
which they were provided with a copy of the guidelines contained
herein and were then asked to score a training set of whole slide
digital images of 60 liver metastases. Subsequently, they were
provided with a validation set comprising 99 additional whole slide
digital images. The scores of this validation set were then used to
compare the participants’ results with the gold standard.
The results of the validation study were tabulated with rows
representing the different participants (n¼ 12) and columns
indicating the percentage of interface occupied by a HGP in the
set of 99 metastases. Using an intraclass correlation coefficient
(ICC), the participants’ scores were compared with the gold
standard, (i.e., the consensus result of the pathologists GGvdE and
PBV). This resulted in ICC coefficients for desmoplastic, pushing,
replacement (type 1), replacement (type 2) and replacement
(independent of type) HGP for each individual participant. ICC
values 40.5 represent a good reproducibility and values 40.7 an
excellent reproducibility. After colour coding and unsupervised
hierarchical clustering of the ICC coefficients of each HGP for all
participants, the heat map (Figure 6) shows that, for the majority of
the participants, good-to-excellent correlations with the gold
standard were obtained for replacement (independent of subtype),
replacement (type 1) and desmoplastic HGP. This indicates that
the key characteristics of the desmoplastic HGP and the
replacement HGP were recognisable by most participants. The
results also show that the participants found the pushing HGP and
the type 2 replacement HGP more difficult to distinguish.
Clinical validation of the guidelines to assess the HGPs of liver
metastases: survival analysis. In order to test the prognostic value
of the growth patterns as scored according to our current guidelines,
the HGPs were scored in CRC liver metastases resection specimens
from a series of 374 patients (Table 4). Correlation of the HGPs with
overall survival was then analysed. For the analysis of overall survival,
the 374 patients were stratified into one of the three subgroups.
Patients for whom 450% of the tumour–liver interface was
identified as desmoplastic HGP were classified as predominant
desmoplastic HGP, while patients for whom450% of the tumour–
liver interface was identified as pushing HGP or replacement HGP
were classified as predominant pushing HGP or predominant
replacement HGP, respectively. According to these criteria, the
desmoplastic HGP was predominant in 183 (49%) patients, the
replacement HGP in 177 (47%) patients and the pushing HGP in 10
(3%) patients. No dominant HGP could be found in the liver
metastases of 4 patients (1%) and so these patients were excluded
from the survival analyses.
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Figure 3. H&E images of the pushing histopathological growth
pattern. (A) Low magnification image of the pushing histopathological
growth pattern. (B and C) Higher magnification images of the pushing
histopathological growth pattern. N, normal liver parenchyma; T, vital
tumour tissue. Scale bar¼ 500mM (A), 100mM (B), 50mM (C).
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Figure 4. H&E images of the replacement histopathological growth
pattern. (A) Low magnification image of the replacement
histopathological growth pattern. (B and C) Higher magnification images
of the type 1 replacement histopathological growth pattern. (D and E)
Higher magnification images of the type 2 replacement histopathological
growth pattern. N, normal liver parenchyma; T, vital tumour tissue. Scale
bar¼2000mM (A), 100mM (B, D and E), 50mM (C).
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Figure 7 shows the overall survival curves for each subgroup.
The median time of follow-up was 34 months (95% CI: 17–61
months). The median overall survival for the desmoplastic
subgroup was 64 months (95% CI: 51–77 months). For the
replacement subgroup median overall survival was 36 months
(95% CI: 30–42 months). Median overall survival was not reached
for the pushing subgroup. Overall survival was significantly
superior in the desmoplastic subgroup as compared with the
replacement or pushing subgroup (P¼ 0.006, Figure 7).
According to Table 5, three parameters were significantly
different between the distinct HGP subgroups: lymph node status
of the primary CRC, absence or presence of metastasis within 1
year after resection of the primary CRC, and systemic treatment
prior resection of liver metastasis. The effects on overall survival of
these parameters were tested in a univariate Cox regression model.
This was also carried out for the clinical risk score (CRS) according
to Fong because of its established prognostic value (Fong et al,
1999) (Table 6). In a multivariate analysis, both a poor CRS (3–5)
and the presence of a predominant replacement HGP resulted in a
significantly shorter overall survival with respective HR of 1.97
(95% CI: 1.47–2.65) and 1.73 (95% CI: 1.28–2.33).
We then repeated the overall survival analysis in order
to determine whether using different cutoffs to define the
predominant HGP would affect the relationship between the
HGP and overall survival. Owing to the low numbers of patients
presenting with a predominantly pushing HGP (only 3% of
patients when using a cutoff of450%), we limited our analysis to a
comparison of overall survival between the replacement HGP
patients versus the desmoplastic HGP patients. Cut points of
450%, 470%, 480%, 490% or 100% were used to define
whether a tumour had a predominant replacement HGP or a
predominant desmoplastic HGP (Table 7). The first thing
that emerges from this analysis is that, predictably, the use of
higher cutoffs incrementally reduces the number of patients eligible
for inclusion in the analysis. For example, while 360 patients
are eligible using a cut point of 450%, this drops to 291
eligible patients using a cut point of 470% and drops to 134
patients using a cut point of 100%. However, overall survival was
significantly superior in the desmoplastic HGP subgroup, as
compared with the replacement HGP subgroup, at all cutoffs
utilised (both by Kaplan–Meier analysis and in multivariate
analysis, Table 7).
N
Figure 5. H&E image of the sinusoidal histopathological growth
pattern. Arrowheads indicate tumour cell emboli present within the
lumen of liver sinusoidal vessels. N, normal liver parenchyma. Scale
bar¼100mM.
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Figure 6. Analytical validation of the guidelines. Heat map of the unsupervised hierarchical clustering of the colour-coded mean intraclass
correlation coefficients of each growth pattern for all observers (n¼12 observers).
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Figure 7. Clinical validation of the guidelines. Kaplan–Meier curves
depicting overall survival of patients with colorectal liver metastases,
stratified by predominant (450%) HGP (n¼ 370 patients).
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DISCUSSION
The current manuscript describes the first guidelines for scoring
the HGPs of liver metastases, based on an international consensus
among experts in the field. Furthermore, we show that, by applying
these guidelines after adequate training, a reproducible assessment
of the HGPs in human specimens of liver metastases is possible. In
addition, it is demonstrated that the HGPs scored according to
these guidelines determine overall survival in patients with liver
metastases of CRC.
Although the scoring can be performed reliably even by non-
specialists and is reproducible between individuals as shown in our
analytical validation study, some limitations were noted, among
them the difficulty of distinguishing the pushing HGP from the
type 2 replacement HGP. This distinction is important, given that
the interaction of the cancer cells with the liver is completely
different in the two HGPs. For example, the pushing growth
pattern relies on sprouting angiogenesis for its vasculature while
the replacement growth pattern co-opts the sinusoidal blood
vessels of the liver (Vermeulen et al, 2001; Van den Eynden et al,
2013; Frentzas et al, 2016).
In the current study, the HGPs scored according to the
proposed guidelines predict outcome: patients with a predominant
desmoplastic HGP have a significant overall survival advantage as
compared with patients with a predominant replacement HGP or
predominant pushing HGP. This is clearly in accordance with the
studies in Table 1 that have addressed the prognostic value of the
Table 5. Clinicopathological characteristics in the final cohort used for clinical validation, excluding 4 patients with a ‘mixed type’
HGP
Desmoplastic (183) Replacement (177) Pushing (10) All patients (N¼370)
Variables Value % or IQR Value % or IQR Value % or IQR P-value Value % or IQR
Male 120 66% 112 63% 6 60% 0.865 238 64%
Age, median 63 56–71 64 59–70 63 58–73 0.591 63 57–70
Primary tumour
Rectal cancer 79 43% 84 48% 4 40% 0.758 167 45%
T3/T4 130 78% 132 79% 8 80% 0.982 270 79%
Positive lymph node 90 55% 113 68% 6 60% 0.049 209 61%
Liver metastases
CEA 4200ngml1 12 8% 11 8% 0 0% 0.892 23 8%
Synchronous (o1 year) 127 70% 102 58% 10 100% 0.004 239 65%
Diameter largest 45 cm 34 19% 30 17% 3 33% 0.484 67 19%
Number of metastases 41 122 67% 105 59% 4 44% 0.165 231 63%
Bilobar 85 46% 63 36% 4 40% 0.112 152 41%
Neo-adjuvant Ctx 110 60% 48 27% 5 50% o0.001 163 44%
R1 resection 49 27% 48 28% 1 10% 0.473 98 27%
Extrahepatic disease 25 14% 18 10% 0 0% 0.298 43 12%
CRS 3–5 64 36% 68 40% 5 50% 0.548 137 38%
Abbreviations: CEA¼ carcinoembryonic antigen; CRS¼ clinical risk score; CTx¼ chemotherapy; HGP¼ histopathological growth pattern; IQR¼ interquartile range.
Table 6. Univariate and multivariate analysis (overall survival)
Univariate HR (95% CI) P-value Multivariate HR (95% CI) P-value
Positive lymph node 1.267 (0.947–1.697) 0.111 Neo-adjuvant CTx 1.224 (0.893–1.678) 0.208
Synchronous (o1 year) 1.162 (0.878–1.537) 0.294 CRS 3–5 (Fong) 1.971 (1.466–2.650) o0.001
Neo-adjuvant CTx 1.280 (0.974–1.681) 0.076 Desmoplastic HGP 1
CRS 3–5 (Fong) 2.005 (1.521–2.642) o0.001 Replacement HGP 1.729 (1.283–2.332) o0.001
Desmoplastic HGP 1 Pushing HGP 1.269 (0.553–2.908) 0.574
Replacement HGP 1.556 (1.181–2.050) 0.019
Pushing HGP 1.435 (0.627–3.283) 0.392
Abbreviations: CI¼ confidence interval; CRS¼ clinical risk score; CTx¼ chemotherapy; HGP¼histopathological growth pattern; HR¼ hazard ratio.
Table 7. Comparison of overall survival in patients with a predominant replacement HGP versus patients with a predominant
desmoplastic HGP (using different %HGP cutoffs to define the predominant HGP)
HGP
cutoff
Total pts in the
analysis
No. of pts
predominant
replacement
No. of pts
predominant
desmoplastic
Kaplan–Meier
P-value
Hazard ratio from multivariate analysis
450% 360 177 183 P¼ 0.001 1.79 (95% CI: 1.31–2.43) Po0.001
470% 291 139 152 P¼ 0.009 1.72 (95% CI: 1.21–2.46) P¼0.003
480% 266 124 142 P¼ 0.005 1.88 (95% CI: 1.29–2.73) P¼0.001
490% 233 108 125 P¼ 0.003 2.13 (95% CI: 1.41–3.20) Po0.001
100% 134 51 83 Po0.001 2.89 (95% CI: 1.66–5.02) Po0.001
Abbreviations: CI¼ confidence interval; HGP¼ histopathological growth pattern.
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HGPs (Okano et al, 2000; Lunevicius et al, 2001; Nystrom et al,
2012; Van den Eynden et al, 2012; Nielsen et al, 2014; Pinheiro
et al, 2014; Eefsen et al, 2015; Frentzas et al, 2016). However, there
are some discrepancies in the reported impact of the replacement
HGP and the pushing HGP on outcome (for details, see Table 1).
These discrepancies may arise due to differences in the patient
cohorts examined and/or due to differences in the way the HGPs
were scored in different studies. For instance, the percentage of
patients who received systemic treatment prior to the resection of
liver metastases may influence the results, as suggested by the
evidence that preoperative therapy may cause a conversion from a
desmoplastic HGP to a replacement HGP (Mentha et al, 2009;
Frentzas et al, 2016). With regards to the methods in which the
HGPs were scored, the cutoffs for classifying a metastasis as having
a predominant HGP differ between different studies, ranging from
50% to 80% of the total length of the interface. Also, the distinction
between the pushing HGP and the type 2 replacement HGP was
not well defined in previous studies. Furthermore, all of these
factors have impacted on the variability documented in the relative
proportions of the different HGPs. Indeed, as an example, the
pushing HGP was reported as the predominant HGP inB7% of all
samples in the study by Frentzas et al (2016) and in B3% of all
samples in the survival study in this manuscript. However, in other
studies, this fraction was as high as 16% (Van den Eynden et al,
2012), 33% (Nielsen et al, 2014), 34% (Eefsen et al, 2015) and even
50% (Nystrom et al, 2012). These issues highlight the need for
standardised and uniform criteria for HGP classification – a major
aim of the present guidelines.
Although we show here that scoring the HGPs of liver
metastases is reproducible, in order to use the HGPs as a
biomarker for treatment decisions it will be necessary to develop
accurate non-invasive surrogate markers for this histopathological
parameter. For example, medical imaging of the liver, such as MRI
or CT scans that are performed routinely in clinical practice, might
eventually be utilised as a surrogate method to determine the HGPs
of liver metastasis. We note that Semelka et al (2000) found that
the presence of transient perilesional enhancement on the MRI
image is correlated with the presence of a desmoplastic reaction
around the rim of liver metastases. However, transient perilesional
enhancement was not present on the MRI image for liver
metastases that lacked a desmoplastic reaction (Semelka et al,
2000). It is therefore possible that transient perilesional enhance-
ment is a potential surrogate marker that distinguishes desmo-
plastic HGP liver metastases from pushing/replacement HGP liver
metastases on MRI scans of the liver. However, a prospective
imaging study performed in a large series of chemotherapy-naive
patients is necessary in order to validate whether this imaging
feature (or other imaging features) can be successfully used to
predict the HGPs of liver metastasis. A study of this sort is
currently ongoing in Sweden (Hanna Nystro¨m, personal commu-
nication). Furthermore, by longitudinal assessment of the HGPs,
through repeated imaging of the same patients, it will also be
possible to appreciate the dynamic nature of the HGPs. This is
relevant because several studies suggest that the HGP of a tumour
can change. For instance, there is evidence that, after systemic
treatment with an antiangiogenic agent, liver metastases can switch
from an angiogenic desmoplastic HGP to the non-angiogenic
replacement HGP (Mentha et al, 2009; Frentzas et al, 2016).
Furthermore, a change from an angiogenic growth pattern to a
non-angiogenic growth pattern upon treatment with antiangio-
genic therapy has also been reported in preclinical models of
hepatocellular carcinoma (Kuczynski et al, 2016), lung metastasis
(Bridgeman et al, 2017), glioblastoma (GBM; Rubenstein et al,
2000) and brain metastasis (Leenders et al, 2004).
There is currently limited understanding of the biological
mechanisms that underlie the different HGPs. Moreover, it is
unclear why some tumours elicit a desmoplastic and angiogenic
response while others grow in a non-angiogenic manner and adopt
the replacement growth pattern. HGPs are, however, a broader
phenomenon not restricted to liver metastases and have also been
described in primary lung cancer (Pezzella et al, 1997) and lung
metastases (Pezzella et al, 1996; Szabo et al, 2015; Bridgeman et al,
2017), primary brain tumours and brain metastases (Sakariassen
et al, 2006; Bugyik et al, 2011; Berghoff et al, 2013; Valiente et al,
2014), lymph node metastases (Naresh et al, 2001; Vermeulen et al,
2002; Jeong et al, 2015) and skin metastases (Colpaert et al, 2003).
Common biological themes, based on the interplay between cancer
cells and the organ microenvironment, may thus be responsible for
the HGPs in different organs.
One working hypothesis to explain the biology of the different
HGPs of liver metastases is that these HGPs recapitulate distinct
reaction patterns of the liver to injury. Two reaction patterns to
liver injury are known, liver fibrosis and liver regeneration, and
they are characterised by specific cytokine profiles (Ding et al,
2014). Fibrosis in the desmoplastic HGP may be mediated by the
same biological mechanisms that drive liver fibrosis in response to
injury. One hallmark of liver fibrosis is ductular reaction, which is
a proliferation of activated cholangiocytes that form small
nonfunctional bile ductular structures (Schuppan and Kim,
2013). Indeed, ductular reaction is also present in the fibrotic
rim of desmoplastic liver metastases (see Figure 2E). The
replacement HGP, on the other hand, resembles liver regeneration,
as cancer cells replace hepatocytes akin to the way that new
hepatocytes replace older hepatocytes during liver regeneration
(Oertel et al, 2006; Dezso et al, 2012). Soluble angiocrine factors
(which are secreted by endothelial cells in sinusoidal blood vessels)
have a major role during liver fibrosis, liver regeneration and in
liver development (Matsumoto et al, 2001; Ding et al, 2010;
Si-Tayeb et al, 2010; Ding et al, 2014). However, the role of these
angiocrine factors in liver metastasis growth patterns is yet to be
elucidated and is currently under investigation.
Desmoplastic and pushing growth pattern tumours are
associated with new vessel formation (via angiogenesis), while
replacement growth pattern tumours are not dependent on
angiogenesis and co-opt preexisting sinusoidal blood vessels
instead (Vermeulen et al, 2001; Stessels et al, 2004; Van den
Eynden et al, 2013; Frentzas et al, 2016). Therefore, another
significant question is: how are these different vascularisation
mechanisms co-ordinated in the liver? Although this is yet to be
elucidated, insight may come from studies performed in GBM.
Similar to the liver metastasis scenario, GBM tumours displaying
either an angiogenic growth pattern or a vessel co-opting growth
pattern have also been described (Sakariassen et al, 2006).
Sakariassen et al (2006) used PDX models of GBM to study what
drives these different growth patterns in the brain. They showed
that, while angiogenic GBMs and vessel co-opting GBMs are
genetically similar (as determined by array CGH), marked
differences in gene expression occur between these growth
patterns. Notably, vessel co-opting GBMs had upregulated
expression of genes associated with foetal development and cell
motility when compared with angiogenic tumours. In contrast,
angiogenic GBMs showed higher expression of angiogenic
regulators, such as VEGF and angiopoetin-2, when compared
with vessel co-opting tumours (Sakariassen et al, 2006). These data
suggest that tumour growth patterns are associated with differences
in tumour gene expression, which may be drivers of the growth
pattern. We are currently undertaking a transcriptomic analysis of
human liver metastases to determine whether similar differences in
gene expression can be found between liver metastases adopting
different growth patterns (Van Laere et al, manuscript in
preparation).
Other studies, performed using preclinical brain metastasis
models, have shown that cancer cells adhere to preexisting brain
vessels during vessel co-option in the brain and that this may be
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mediated by distinct cell adhesion molecules expressed by cancer
cells, such as b1-integrins or L1CAM (Dome et al, 2003; Carbonell
et al, 2009; Bugyik et al, 2011; Valiente et al, 2014). In the
replacement growth pattern of liver metastases, our histopatholo-
gical observations suggest that cancer cells also adhere to the
sinusoidal blood vessels. Moreover, others have reported that
‘adhesive co-option’ of sinusoidal blood vessels by cancer cells,
mediated by integrins, has a role in liver metastasis (Kemperman
et al, 1997). Taken together, these data suggest that the propensity
for cancer cells to adopt a specific growth pattern may also involve
important changes in the ability of cancer cells to adhere to
preexisting blood vessels.
In addition, the progression of cancer along preexisting
basement membranes (as observed in the replacement growth
pattern) clearly resembles what pathologists recognise as in situ
carcinoma, a presentation in which cancer cells respect the existing
structure of the host organ. Although this is typically a feature that
has been described to occur in primary tumours (i.e., occurring
prior to invasion and subsequent metastasis), reversion of
metastatic cancer to this in situ phase has indeed been documented
in other sites, for instance, in lymph node metastases (Barsky et al,
1997). Therefore, the adoption of the replacement growth pattern
may also represent a form of reversion to in situ tumour growth.
We find that, while approximately one-third of patients present
with a ‘pure’ growth pattern (i.e., 100% desmoplastic, 100%
pushing or 100% replacement HGP), approximately two-thirds of
patients present with a mixed growth pattern. Unfortunately, the
biological basis for this heterogeneity of growth pattern within the
same patient remains unclear. However, future studies aimed at
addressing the molecular mechanisms that underlie the growth
patterns should provide insight as to the basis for this
heterogeneity. As for the practical significance of a mixed growth
pattern, it is apparent that, even when a mixture of growth patterns
is present, the predominant growth pattern can still have a
significant effect on patient outcome. For example, around two-
thirds of the patients included in our overall survival analysis
(using the 450% cut point) presented with a mixture of growth
patterns, and yet the predominant growth pattern still had a
statistically significant effect on overall survival. There is also
evidence that treatment with standard therapies can alter the
growth pattern of liver metastases from desmoplastic to replace-
ment (Mentha et al, 2009; Frentzas et al, 2016). It is therefore
possible that, in some cases, liver metastases with a mixed growth
pattern represent those tumours that are in a state of transition
from one growth pattern to another. If it is the case that standard
therapies can indeed drive a shift in growth pattern from a good
prognosis pattern (i.e., desmoplastic) to a bad prognosis
pattern (i.e., replacement), then it may be necessary to derive
therapeutic strategies that can either prevent or combat this
adverse transition.
In conclusion, we provide clear and reproducible guidelines for
scoring the HGPs of liver metastasis. The HGPs have a prognostic
and predictive value for patients with liver metastatic CRC as
demonstrated here and in other retrospective studies (Okano et al,
2000; Lunevicius et al, 2001; Nystrom et al, 2012; Van den Eynden
et al, 2012; Nielsen et al, 2014; Pinheiro et al, 2014; Eefsen et al,
2015; Frentzas et al, 2016). Prospective studies based on large
cohorts of patients, and preferably linked to clinical trials, are now
needed to confirm the clinical value of the HGPs and to assess the
value of medical imaging, or circulating molecular markers, as
potential surrogate biomarkers for the HGPs. Moreover, further
studies are now warranted to understand the molecular mechan-
isms that underlie the HGPs, because these may eventually lead to
HGP-specific treatment strategies for liver metastases. This could
pave the way for an improved selection strategy for the type of
systemic treatment before and/or after liver surgery and for
personalised risk-adapted follow-up strategies.
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